EXPORT CITATION

Chapter-014b Premixed Insulin

BOOK TITLE: ESI Manual of Clinical Endocrinology

Author
1. Das Ashok Kumar
2. Kalra Sanjay
ISBN
9789351526476
DOI
10.5005/jp/books/12535_17
Edition
2/e
Publishing Year
2015
Pages
4
Author Affiliations
1. Jawaharlal Institute of Postgraduate Medical, Education and Research (JIPMER), Puducherry, India, J.I.P.M.E.R., Pondicherry, Indian Institute of Diabetes, Thiruvananthapuram, Jawaharlal Institute of Postgraduate Medical, Education and Research, Puducherry, India, Jawaharlal Institute for Postgraduate, Medical Education and Research (JIPMER), Puducherry, India, Pondicherry Institute of Medical Sciences, Puducherry, India, Institution of Medical Sciences, Puducherry, India
2. Bharti Hospital, Karnal, Haryana, India, Bharti Hospital and B.R.I.D.E., Karnal 132 001, Haryana, India, Bharti Hospital and BRIDE Karnal; Indian J Endocrinology Metabolism, Bharti Hospital, Karnal, Haryana, India, Bharti Hospital, Karnal-132001, Haryana, India, Indian J Endocrinology and Metabolism; J of Social Health in Diabetes (JoSH Diabetes), Bharti Hospital and BRIDE, Karnal, Haryana, India, Bharti Hospital and BRIDE, Karnal, Haryana, India
Chapter keywords
Premixed Insulin, BHI, biphasic insulin aspart, biphasic insulin lispro, premix biphasic insulin analogs, basal insulins

Abstract

Premixed biphasic human insulin (BHI), NPH, premix biphasic insulin analogs and basal insulins are several insulin regimens which have longer acting effect as compared to the natural insulin. BHI, biphasic insulin aspart (BiAsp) and biphasic insulin lispro (lispro mix) are the currently available three premix formulations. There are two main components of premix BHI/biphasic insulin analogs: rapid acting component and the intermediate acting component. Premix insulin is suitable for the patients who are willing to follow a regular diet plan and who wish to take intensive insulin therapy. This chapter explains about many case studies about the efficacy and safety of premix insulin initiation with insulin. Dose of premix insulin may be high in the case of intensive therapy or may be lower in some cases. The dosage of premix human insulin varies from the dosage of premix analog insulin which shows significant efficacy and safety. Hypoglycemia, cost factor, weight gain and compliance-related issues are some of the factors which should be considered.

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved